2-[4-(3-ethoxy-trans-1-propen-1-yl)phenyl]-4-(4-N,N-diethylaminophenyl)-5-(4-N-methylaminophenyl) imidazole | 216227-22-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[4-(3-ethoxy-trans-1-propen-1-yl)phenyl]-4-(4-N,N-diethylaminophenyl)-5-(4-N-methylaminophenyl) imidazole
• 英文别名: 4-[4-[4-(diethylamino)phenyl]-2-[4-[(E)-3-ethoxyprop-1-enyl]phenyl]-1H-imidazol-5-yl]-N-methylaniline
• CAS: 216227-22-4
• 化学式: C₃₁H₃₆N₄O
• 分子量: 480.653
• InChiKey: FPWPBZGPPLHIBB-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  53.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4,4'-二氟苯偶酰 在 ammonium acetate 、 potassium carbonate 、 溶剂黄146 作用下， 以 二甲基亚砜 为溶剂， 生成 2-[4-(3-ethoxy-trans-1-propen-1-yl)phenyl]-4-(4-N,N-diethylaminophenyl)-5-(4-N-methylaminophenyl) imidazole
  参考文献：
  名称：

  2,4,5-Trisubstituted imidazoles

  摘要：

  Solution-phase combinatorial chemistry was applied to the optimization and development of clinical candidate OC144-093 (22), a novel and nontoxic modulator of P-glycoprotein mediated multidrug resistance. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00521-7

文献信息

• Use of a substituted imidazole, derivatives or salts thereof for the preparation of a medicament for the treatment of a cell proliferative disorder
  申请人：Taiji Biomedical, Inc.

  公开号：EP2064951A1

  公开（公告）日：2009-06-03

  The present invention relates to the use of a compound having the formula I, a derivative or a salt thereof for the preparation of a medicament for the treatment of a cell proliferative disorder, wherein the cell proliferative disorder is further treated by a chemotherapeutic agent

  本发明涉及一种具有式 I 的化合物、其衍生物或盐用于制备治疗细胞增殖性疾病的药物，其中细胞增殖性疾病由化疗药物进一步治疗
• Use of imidazole derivatives as MDR modulators
  申请人：Taiji Biomedical, Inc.

  公开号：EP2082740A2

  公开（公告）日：2009-07-29

  The invention relates to the use of imidazole derivatives having formula (I) or their pharmaceutically acceptable salts for treating tumor cells and for increasing the sensitivity of multidrug resistant tumor cells to antitumor chemotherapeutic agents.

  本发明涉及具有式 (I) 的咪唑衍生物的用途 或其药学上可接受的盐类用于治疗肿瘤细胞和提高耐多药肿瘤细胞对抗肿瘤化疗药物的敏感性。
• Methods and compositions for enhancing pharmaceutical treatments
  申请人：——

  公开号：US20020147197A1

  公开（公告）日：2002-10-10

  Improved methods are provided for therapeutic and/or preventative treatment to a mammal in which the mammal is protected against the toxicity of active pharmaceutical agents that (i) bind to or are substrates for P-gp, (ii) are taxane analogues, and/or (iii) are inhibitors of tubulin disassembly. Additionally provided are compositions and methods useful for treating cell proliferative disorders. Further provided are methods of increasing the bioavailability of therapeutic and/or preventative treatments in a mammal. Particular embodiments are directed to increasing such bioavailability across the blood-brain barrier.

  本发明提供了对哺乳动物进行治疗和/或预防性治疗的改进方法，其中哺乳动物可免受以下活性药物的毒性：(i) 与 P-gp 结合或 P-gp 底物，(ii) 紫杉类类似物，和/或 (iii) 管蛋白分解抑制剂。此外，还提供了用于治疗细胞增殖性疾病的组合物和方法。还提供了提高哺乳动物体内治疗和/或预防治疗的生物利用度的方法。具体的实施方案是提高这种通过血脑屏障的生物利用度。
• EP0999835A4
  申请人：——

  公开号：EP0999835A4

  公开（公告）日：2004-08-25
• IMIDAZOLE DERIVATIVES AS MDR MODULATORS
  申请人：Taiji Biomedical, Inc.

  公开号：EP0999835B1

  公开（公告）日：2009-09-09